undamentalytics Newsletter
Sign in

Geovax Labs, Inc. income statement

In fiscal 2025, Geovax Labs, Inc. reported revenue of $2.5m, down 37.1% on the year before, operating income of −$21.6m (a -869.3% margin) and net income of −$21.5m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11112000420
Research and development2222216921241815
General and administrative21222456565
Operating income−3−2−3−2−3−19−14−27−25−22−21
Interest expense——00000000—
Income tax000000———00
Net income−3−2−3−2−3−19−14−26−25−21−20
Diluted EPS−$0.40−$3.75−$1951291.25−$97733.75−$267.50−$15.20—————
Diluted shares (average)————11m——————
EBITDA−3−2−3−2−3−19−14−27−25−22−20

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Geovax Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Geovax Labs, Inc.